https://www.selleckchem.com/products/tl12-186.html
Upon detailed analysis this resulted in the identification of a total of 84 studies. We identified 52 publications and 32 registered trials that investigate small molecules for their safety and efficacy as treatment for different aspects of epidermolysis bullosa. Further, a total of 38 different small molecules clinically used in EB were found. Most frequent outcome measures concerned wound healing, reduction in blister numbers, as well as reduction of itch and pain, predominantly for EBS and RDEB. We provide a comprehensive summary of